/
Other
Atorvastatin
11
Pipeline Programs↗
5
Active Trials↗
39
Companies Involved↗
Atorvastatin is an emerging landscape with 11 programs across 39 companies. The most active players are Guangdong Raynovent Biotech Co., Ltd, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Onconic Therapeutics Inc.. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 17
Approved
No programs
Analysis
Trial Status
173
clinical trials
Completed138 · 80%
Unknown status23 · 13%
Terminated4 · 2%
Recruiting3 · 2%
Withdrawn3 · 2%
Active, not recruiting1 · 1%
Other1 · 1%
Clinical Trials
Trial Activity
173 trials
Effect of Nigella Sativa in Atorvastatin Treated Hyperlipidaemia
Recruiting·—·Phase 2·NCT06422650·84 enrolled
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study)
Completed·—·Phase 4·NCT03228771·30 enrolled
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
Completed·—·Phase 4·NCT00166504·203 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)